Literature DB >> 21887526

Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.

M-C Chiang1, S-C Kuo, S-J Chen, S-P Yang, Y-T Lee, T-L Chen, C-P Fung.   

Abstract

PURPOSE: Acinetobacter baumannii, Acinetobacter genomic species 3 (AGS 3), and Acinetobacter genomic species sensu Tjernberg and Ursing (AGS 13TU) are phenotypically indistinguishable and are often reported together as the A. baumannii complex (ABC). Few studies have investigated the difference in outcome caused by these different species, and all involved heterogeneous groups of patients. This study aimed to delineate whether there are differences in the clinical characteristics and outcome among patients with solid tumors and bacteremia caused by A. baumannii or two other non-baumannii ABC species (AGS 3 plus AGS 13TU).
METHODS: Patients with solid tumors and ABC bacteremia over a period of 5 years in a medical center were identified. The patient data were retrospectively reviewed and analyzed.
RESULTS: We identified 103 patients with ABC bacteremia during the study period. Bacteremia was due to A. baumannii in 30 patients, AGS 3 in 24 patients, and AGS 13TU in 49 patients. Among the 103 patients with ABC bacteremia, recent stay in the intensive care unit (ICU) (p = 0.008) was independently associated with the acquisition of A. baumannii bacteremia. Multivariate analysis revealed that bacteremia caused by A. baumannii (hazard ratio [HR] 2.990, 95% confidence interval [CI], 1.021-8.752, p = 0.046) and Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥21 (HR 4.623, 95% CI 1.348-15.859, p = 0.015) were independent factors associated with 14-day mortality.
CONCLUSIONS: Infection with A. baumannii and a high APACHE II score (≥21) might be associated with poor outcome in patients with solid tumors and ABC bacteremia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21887526     DOI: 10.1007/s15010-011-0187-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  42 in total

Review 1.  Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance.

Authors:  Nicola C Gordon; David W Wareham
Journal:  Int J Antimicrob Agents       Date:  2010-01-04       Impact factor: 5.283

2.  Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients.

Authors:  J L García-Garmendia; C Ortiz-Leyba; J Garnacho-Montero; F J Jiménez-Jiménez; J Monterrubio-Villar; M Gili-Miner
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

Review 3.  Clinical impact and pathogenicity of Acinetobacter.

Authors:  M-L Joly-Guillou
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

4.  Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features.

Authors:  J M Cisneros; M J Reyes; J Pachón; B Becerril; F J Caballero; J L García-Garmendía; C Ortiz; A R Cobacho
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

5.  Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Authors:  H Wisplinghoff; M B Edmond; M A Pfaller; R N Jones; R P Wenzel; H Seifert
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

6.  Molecular characterization of carbapenem-resistant Acinetobacter species in an Irish university hospital: predominance of Acinetobacter genomic species 3.

Authors:  T W Boo; F Walsh; B Crowley
Journal:  J Med Microbiol       Date:  2009-02       Impact factor: 2.472

7.  Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology.

Authors:  D Villers; E Espaze; M Coste-Burel; F Giauffret; E Ninin; F Nicolas; H Richet
Journal:  Ann Intern Med       Date:  1998-08-01       Impact factor: 25.391

8.  Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan.

Authors:  Yi-Tzu Lee; Li-Yueh Huang; Dung-Hung Chiang; Chien-Pei Chen; Te-Li Chen; Fu-Der Wang; Chang-Phone Fung; Leung-Kei Siu; Wen-Long Cho
Journal:  Int J Antimicrob Agents       Date:  2009-09-03       Impact factor: 5.283

9.  Significance of genomic DNA group delineation in comparative studies of antimicrobial susceptibility of Acinetobacter spp.

Authors:  Elizabeth T S Houang; Yiu Wai Chu; K Y Chu; K C Ng; C M Leung; A F B Cheng
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit.

Authors:  Ji Ye Jung; Moo Suk Park; Song Ee Kim; Byung Hoon Park; Ji Young Son; Eun Young Kim; Joo Eun Lim; Sang Kook Lee; Sang Hoon Lee; Kyung Jong Lee; Young Ae Kang; Se Kyu Kim; Joon Chang; Young Sam Kim
Journal:  BMC Infect Dis       Date:  2010-07-30       Impact factor: 3.090

View more
  13 in total

1.  Outer membrane Protein A plays a role in pathogenesis of Acinetobacter nosocomialis.

Authors:  Sang Woo Kim; Man Hwan Oh; So Hyun Jun; Hyejin Jeon; Seung Il Kim; Kwangho Kim; Yoo Chul Lee; Je Chul Lee
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

Review 2.  Bloodstream infections in patients with solid tumors.

Authors:  Carlota Gudiol; José María Aguado; Jordi Carratalà
Journal:  Virulence       Date:  2016-01-19       Impact factor: 5.882

3.  Non-fermentative Gram-negative rods bacteremia in children with cancer: a 14-year single-center experience.

Authors:  D Averbuch; C Avaky; M Harit; P Stepensky; I Fried; T Ben-Ami; V Temper; Y Peled; H Troen; R Masarwa; W Abu Ahmad; M Weintraub; S Revel-Vilk; D Engelhard
Journal:  Infection       Date:  2017-02-15       Impact factor: 3.553

4.  Outcomes of critically ill cancer patients with Acinetobacter baumannii infection.

Authors:  Silvio A Ñamendys-Silva; Paulina Correa-García; Francisco J García-Guillén; María O González-Herrera; Américo Pérez-Alonso; Julia Texcocano-Becerra; Angel Herrera-Gómez; Patricia Cornejo-Juárez; Abelardo Meneses-García
Journal:  World J Crit Care Med       Date:  2015-08-04

5.  Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance.

Authors:  Margaret A Fitzpatrick; Egon Ozer; Maureen K Bolon; Alan R Hauser
Journal:  J Infect       Date:  2014-09-19       Impact factor: 6.072

6.  Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant A.baumannii in Cancer Patient.

Authors:  Wasan Katip; Suriyon Uitrakul; Peninnah Oberdorfer
Journal:  Antibiotics (Basel)       Date:  2021-04-22

7.  The success of acinetobacter species; genetic, metabolic and virulence attributes.

Authors:  Anton Y Peleg; Anna de Breij; Mark D Adams; Gustavo M Cerqueira; Stefano Mocali; Marco Galardini; Peter H Nibbering; Ashlee M Earl; Doyle V Ward; David L Paterson; Harald Seifert; Lenie Dijkshoorn
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

8.  Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients.

Authors:  Wasan Katip; Suriyon Uitrakul; Peninnah Oberdorfer
Journal:  Infect Drug Resist       Date:  2017-09-07       Impact factor: 4.003

9.  Rapid detection of Acinetobacter baumannii and molecular epidemiology of carbapenem-resistant A. baumannii in two comprehensive hospitals of Beijing, China.

Authors:  Puyuan Li; Wenkai Niu; Huan Li; Hong Lei; Wei Liu; Xiangna Zhao; Leijing Guo; Dayang Zou; Xin Yuan; Huiying Liu; Jing Yuan; Changqing Bai
Journal:  Front Microbiol       Date:  2015-09-23       Impact factor: 5.640

Review 10.  The Acinetobacter baumannii group: a systemic review.

Authors:  Hua-Zhong Zhang; Jin-Song Zhang; Li Qiao
Journal:  World J Emerg Med       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.